Certara Announces Sale of Regulatory and Medical Writing Business to Veristat for Up to \$135 Million
Key Points for Investors
- Definitive Agreement Signed: Certara, Inc. (Nasdaq: CERT) has entered a definitive agreement to sell its Regulatory and Medical Writing business to Veristat for up to \$135 million. The transaction is expected to close in Q2 2026, pending customary closing conditions.
- Strategic Refocus: The sale aligns with Certara’s strategy to sharpen its focus on Model-Informed Drug Development (MIDD) and Clinical Intelligence, particularly accelerating AI-integrated modeling and simulation capabilities.
- Financial Impact: In 2025, the divested business generated \$50 million in revenue and \$17 million in adjusted EBITDA (excluding unallocated overhead). This significant revenue and profit stream will be removed from Certara’s consolidated results post-sale.
- Employee Transition: Approximately 220 employees are expected to transfer to Veristat as part of the transaction.
- Use of Proceeds: Certara plans to deploy the sale proceeds to accelerate investment in its core MIDD platform, product innovation, and operational excellence, aiming to drive long-term shareholder value.
- Updated Guidance: The company will provide updated 2026 financial guidance upon transaction close, which may have a material effect on future expectations.
Details of the Transaction
Certara’s CEO, Jon Resnick, emphasized that the sale is a key step in expanding the scale, reach, and impact of its MIDD and Clinical Intelligence solutions. The transaction underlines Certara’s commitment to integrating AI-driven modeling and simulation across the drug development lifecycle – a move that could potentially enhance Certara’s competitive positioning and growth prospects in the high-tech drug development sector.
The Regulatory and Medical Writing business represents a meaningful portion of Certara’s current revenue and profitability, with \$50 million in revenue and \$17 million in adjusted EBITDA for 2025. The sale price of up to \$135 million suggests an attractive multiple, but its removal from Certara’s financials will impact future revenue and earnings figures. Investors should closely monitor the upcoming updated 2026 guidance that will be provided after the transaction’s close.
Certara’s management highlighted that the proceeds from the sale will be reinvested into the company’s core areas. This is consistent with Certara’s long-term strategy to focus on innovation and operational excellence in the MIDD space, which management believes will generate greater value for customers, patients, and shareholders over time.
The deal team includes Perella Weinberg Partners LP as Certara’s financial advisor and Troutman Pepper Locke LLP as legal counsel. Veristat was advised by Guggenheim Securities, LLC and McDermott Will & Schulte.
Potential Price-Sensitive Information and Shareholder Considerations
- Material Change to Business Mix: The divestiture will materially alter Certara’s business mix and financial profile. The removal of a \$50 million revenue stream (with strong EBITDA margins) may influence valuation metrics and investor sentiment in the short term.
- Strategic Focus and Reinvestment: Certara’s intention to redeploy proceeds into its core MIDD platform indicates a bet on higher-growth, higher-margin opportunities. The success of this reinvestment will be critical for long-term shareholder value.
- Guidance Update Pending: Updated financial guidance for 2026 will be provided after the transaction closes. This update will be crucial for investors to reassess Certara’s near- and medium-term outlook.
- Transaction Risks: There are standard closing risks, including regulatory approvals, customer and shareholder reactions, and possible disruptions during the transition.
Forward-Looking Statements and Risks
Management cautions that forward-looking statements, including expectations about the transaction, its closing timeline, use of proceeds, and future performance, are subject to risks and uncertainties. These include the possibility the transaction does not close, unanticipated costs or delays, customer and shareholder reactions, and general economic conditions. Investors are encouraged to review the company’s SEC filings (including the latest Form 10-K) for a full list of potential risks.
Contact Information
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Please refer to Certara’s official filings and press releases for complete and up-to-date information. Investors should consult their financial advisors regarding the impact of this transaction on their investment decisions.
View Certara, Inc. Historical chart here
